RESUMO
Pancreatic cancer is a fatal disease. The survival rate of patients with all stages of pancreatic cancer is very low, and most patients die of chemotherapy-resistant metastatic diseases. Gemcitabine has been used as the standard treatment for pancreatic cancer for more than 20 years, but as a single drug, gemcitabine can not completely cure pancreatic cancer. In the past decades, great efforts have been made to develop effective treatments for pancreatic cancer. This review describes the research status of targeted therapy drugs for pancreatic cancer in recent years, introduces drugs for common molecular characteristics of pancreatic cancer, and develops combined therapy based on metastasis mechanism. In the era of molecular targeting, targeted therapy for pancreatic cancer is expected to become a breakthrough in the treatment.